阿卡波糖治疗2型糖尿病短期成本-效果比较

Short-term cost-effectiveness analysis of acarbose for type 2 diabetes mellitus

比较国产与原研阿卡波糖治疗2型糖尿病的短期成本效果。回顾分析2015年3—12月采用二甲双胍、吡咯列酮和阿卡波糖联合治疗的患者,A组(国产)32例,B组(原研)32例,观察一个月后的指标。两组患者给药治疗后平均血糖和糖化血红蛋白(Hb A1c)均产生了显著下降,两组效果无显著性差异,A组有效率65.63%,B组有效率71.87%。以餐后2 h血糖为标准的成本-效果,国产阿卡波糖较优;以空腹血糖和Hb A1c为标准的成本-效果,原研阿卡波糖较优。国产与原研阿卡波糖都有较好的降糖效果,在降低餐后2 h血糖方面,国产阿卡波糖效价比更优;在降低空腹血糖和Hb A1c方面,原研阿卡波糖疗效占优。

The short-term cost-effectiveness of domestic and imported acarbose tablets were compared in the treatment of type 2 diabetic mellitus. The patients with combined treatment by metformin, pioglitazone and acarbose from March 2015 to December 2015 were classified into two groups： 32 cases in group A treated with domestic acarbose and 32 cases in group B treated with imported acarbose. Within one month tracing study, the patients in both groups showed a significant reduction in both average blood glucose and Hb A1 c, and there was no significant difference between the two groups. The effective rates of group A and group B were 65.63% and71.87% respectively. Both domestic and imported acarbose exhibited a good hypoglycemic effect.Domestic acarbose had a better cost-effectiveness based on postprandial 2 h blood glucose as investigation index, while imported acarbose had a better cost-effectiveness with fasting blood glucose and Hb A1 c as investigation index.